Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings

Open Forum Infectious Diseases

Volumn 1, Issue 2, 2014, Pages

  Bahr, Nathan C ^a,b,c   Rolfes, Melissa A ^a,b   Musubire, Abdu ^c   Nabeta, Henry ^c   Williams, Darlisha A ^a,b,c   Rhein, Joshua ^a,b,c   Kambugu, Andrew ^a,b,c   Meya, David B ^a,b,c   Boulware, David R ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

Author keywords

Amphotericin; Cryptococcal meningitis; HIV AIDS; Potassium; Side effect

Indexed keywords

AMPHOTERICIN; BICARBONATE; FLUCONAZOLE; MAGNESIUM ION; POTASSIUM ION; SODIUM ION;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CLINICAL TRIAL; COHORT ANALYSIS; CRYPTOCOCCAL MENINGITIS; ELECTROLYTE SUPPLEMENTATION; FEMALE; FLUID THERAPY; GLASGOW COMA SCALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOMAGNESEMIA; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; VIRUS LOAD;

EID: 84943383489     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu070     Document Type: Article

References (33)

1. Jarvis JN, Meintjes G, Williams A, et al. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010; 10:67.
2. Durski KN, Kuntz KM, Yasukawa K, et al. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr 2013; 63:e101-8.
3. Cohen DB, Zijlstra EE, Mukaka M, et al. Diagnosis of cryptococcal and tuberculous meningitis in a resource-limited African setting. Trop Med Int Health 2010; 15:910-7.
4. Castelnuovo B, Manabe YC, Kiragga A, et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49:965-72.
5. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-30.
6. French N, Gray K,Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031-8.
7. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007; 12:929-35.
8. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291-322.
9. World Health Organization. Rapid advice: Diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: World Health Organization, 2011.
10. Rajasingham R, Rolfes MA, Birkenkamp KE, et al. Cryptococcal meningitis treatment strategies in resource-limited settings: a costeffectiveness analysis. PLoS Med 2012; 9:e1001316.
11. Girmenia C, Gentile G, Micozzi A, et al. Nephrotoxicity of amphotericin B desoxycholate. Clin Infect Dis 2001; 33:915-6.
12. Gallis HA, Drew RH, PickardWW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-29.
13. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003; 36:943-51.
14. Mayer J, Doubek M, Vorlicek J. Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 1999; 7:51-5.
15. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694-701.
16. Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202:962-70.
17. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 2010; 7:e1000384.
18. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 2014; 370:2487-98.
19. Loyse A,Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012; 54:121-8.
20. Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009; 48:1775-83.
21. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviralnaive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.
22. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
23. Bamba AV, Jadhav MP, Prabhu R, et al. Refractory hypokalemia due to conventional amphotericin B in patients with leukemia. Indian J Cancer 2009; 46:76-7.
24. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27:296-302.
25. McChesney JA, Marquardt JF. Hypokalemic paralysis induced by amphotericin B. JAMA 1964; 189:1029-31.
26. Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002; 186: 379-88.
27. Muzoora CK, Kabanda T, Ortu G, et al. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 2012; 64:76-81.
28. Jackson AT, Nussbaum JC, Phulusa J, et al. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with shortcourse amphotericin B, for cryptococcal meningitis. AIDS 2012; 26:1363-70.
29. Pennington JAT, Youngt B. Sodium, potassium, calcium, phosphorus, and magnesium in foods from the United States total diet study. J Food Compost Anal 1990; 3:145-65.
30. Joint Medical Store. Potassium chloride slow-release 600mg tablet (Product catalog). Available at: http://www.jms.co.ug/resources. Accessed 1 September 2013.
31. Day JN, Chau TT,Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. PLoS Med 2013; 368:1291-302.
32. Bahr N, Rolfes MAR, Musubire A, et al. The impact of routine electrolyte supplementation during amphotericin induction therapy in resource-limited settings. In: 8th International Conference on Cryptococcus and Cryptococcosis. Charleston, SC, 2011.
33. Rhein J, Boulware DR. Prognosis and management of cryptococcal meningitis in patients with human immunodeficiency virus infection. Neurobehavioral HIV Med 2012; 4:45-61.